Results 141 to 150 of about 774,346 (269)

STING Agonist-Modified Tumor Targeting Photosensitizer Remodels Cancer-Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer. [PDF]

Adv Sci (Weinh)
Zhang Y, Yao S, Zhao Y, Zhu S, Fang W, Yu R, Shi N, Zhang R, Zhang Y, Liang J, Zhang Z, Xu S, Zhang Z, Zhang J, Li Y, Han X, Chen Y, Zhang S, Lv Y.   +18 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Electrochemically Engineered GQDs for Selective Tumor Targeting and Oxidative Nanotherapy in Triple-Negative Breast Cancer. [PDF]

ACS Omega
Dar MS, Sahu NK.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Tumor-targeting bioluminescent bacteria for <i>in vivo</i> imaging. [PDF]

Eng Microbiol
Ma C, Liu J, Liu H, Zhao X, Li G, Zhang Y, Jiang T.   +6 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Author Correction: Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity

Scientific Reports
Yingying Huang, Qiqi Mao, Jian He, Jing Su, Yi Peng, Wei Liang, Zixi Hu, Sufang Zhou, Xiaoling Lu, Yongxiang Zhao   +9 more
doaj   +1 more source

Unlocking the potential of tumor-targeting peptides in precision oncology. [PDF]

Oncol Res
Rehman HM, Ahmad S, Sarwar A, Bashir H.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Correction: Novel anti-CEA affibody for rapid tumor-targeting and molecular imaging diagnosis in mice bearing gastrointestinal cancer cell lines. [PDF]

Front Microbiol
Shao H, Lv K, Wang P, Jin J, Cai Y, Chen J, Kamara S, Zhu S, Zhu G, Zhang L.   +9 more
europepmc   +1 more source